March 26 (Bloomberg) — Abandoning a long-held industry tradition, GlaxoSmithKline Plc and Merck & Co. won't help low-income Obamacare patients pay for their high-priced drugs.

The drugmakers say they won't provide the assistance until the government decides whether programs overseen by the U.S. health-care act are subject to federal laws banning kickbacks that steer business to companies. So far, U.S. agencies have sent mixed messages on the issue, industry officials said.

Historically, drugmakers use coupons and debit cards to encourage the use of high-priced medicines rather than less expensive older treatments and generics pushed by insurers using high co-pays as a cudgel. In the case of Amgen Inc.'s Neulasta for chemotherapy patients, the company pays as much as $10,000 a year to help patients get the medicine. Amgen is among a group of companies continuing their aid programs.

"This can be a significant issue for a middle-income family," said Mit Spears, general counsel at Pharmaceutical Research and Manufacturers of America, or PhRMA, the Washington- based lobbying group for the industry. "I have a real hard time, just as a conceptual model, thinking the help you give a patient could be viewed as a kickback."

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events
  • Access to other award-winning ALM websites including and

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.